| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/21/2006 | CA2178949C Morpholine and thiomorpholine tachykinin receptor antagonists |
| 03/21/2006 | CA2139112C Novel nicotinic acid esters |
| 03/21/2006 | CA2129771C Phenylalkanolamine derivatives |
| 03/21/2006 | CA2072416C Cyclopropenone derivatives |
| 03/16/2006 | WO2006029349A1 Combination of organic compounds |
| 03/16/2006 | WO2006029275A2 Methods of using death receptor ligands and cd20 antibodies |
| 03/16/2006 | WO2006028957A1 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 03/16/2006 | WO2006028904A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | WO2006028290A1 2-morpholino-4-pyrimidone compound |
| 03/16/2006 | WO2006028239A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | WO2006028122A1 Agent for preventing and ameliorating obesity |
| 03/16/2006 | WO2006027692A2 Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 03/16/2006 | WO2006027691A2 Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| 03/16/2006 | WO2006027579A2 The treatment of inflammatory disorders and pain |
| 03/16/2006 | WO2006027366A1 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| 03/16/2006 | WO2006027252A1 Sigma receptor ligands |
| 03/16/2006 | WO2006027226A1 Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| 03/16/2006 | WO2006027221A1 Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| 03/16/2006 | WO2006027130A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 03/16/2006 | WO2006027052A2 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 03/16/2006 | WO2006005609A3 Substituted oxindol derivatives and medicaments containing the same |
| 03/16/2006 | WO2005123081A3 (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
| 03/16/2006 | WO2005121168A3 Heparin binding peptide |
| 03/16/2006 | WO2005115453A3 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies |
| 03/16/2006 | WO2005106488A3 Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2) |
| 03/16/2006 | WO2005092873A3 Thiadiazoles for treatment of cancer or neurological disease |
| 03/16/2006 | WO2005063745A3 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 03/16/2006 | WO2005030260A8 Bispecific oligonucleotide for the treatment of cns malignancies |
| 03/16/2006 | WO2005016884A9 Cyclopropyl derivatives as nk3 receptor antagonists |
| 03/16/2006 | US20060059576 Treatment of neurodegenerative conditions with nimesulide |
| 03/16/2006 | US20060058553 Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| 03/16/2006 | US20060058552 Solid preferably with an aspect ratio of 1 to 4 and a solubility in water at room temperature of at least 425 mg/ml. |
| 03/16/2006 | US20060058504 Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases |
| 03/16/2006 | US20060058398 Medicinal compositions containing vitamin k's as nerve growth factor potentiator and utilization thereof |
| 03/16/2006 | US20060058394 Medicine of post-traumatic stress disorder |
| 03/16/2006 | US20060058392 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 03/16/2006 | US20060058376 Composition having autonomic nerve modulating activity and method of use thereof |
| 03/16/2006 | US20060058373 Novel substituted sulfamate anticonvulsant derivatives |
| 03/16/2006 | US20060058371 Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease |
| 03/16/2006 | US20060058366 Jnk inhibitor |
| 03/16/2006 | US20060058364 Treatment of dependence and dependence related withdrawal symptoms |
| 03/16/2006 | US20060058360 Heteroaryloxy/thio propanamines; improved acid stability, potency and selectivity to the dopamine transporter; improved ADME properties e.g. reduced tendency to act as a substrate and/or inhibitor the enzyme Cytochrome P450; pain; [(3R)-3-(Isoquinolin-4-yloxy)-3-phenyl-propyl]-methyl-amine hydrochloride |
| 03/16/2006 | US20060058354 Conjugated aromatic compounds with a pyridine substituent |
| 03/16/2006 | US20060058349 Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |
| 03/16/2006 | US20060058348 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors |
| 03/16/2006 | US20060058336 Pharmaceutical composition for treatment of drug dependence |
| 03/16/2006 | US20060058333 Analgesic compositions containing buprenorphine |
| 03/16/2006 | US20060058332 sublingual administration of N-cyclopropylmethyl-7 alpha -[1-(S)-hydroxy-1,2,2-trimethylpropyl]6,14-endoethano-6,7,8,14-tetrahydro-nororipavine, in combination with naloxone, naltrexone or nalmefene; synergistic mixtures for the treatment of pain in humans or animals |
| 03/16/2006 | US20060058329 Pyrazole inhibitors of the transforming growth factor |
| 03/16/2006 | US20060058320 [1,2,4] Triazolo[1,5-c]pyrimidine derivatives |
| 03/16/2006 | US20060058316 Side effect reduction; asthma; antiinflammatory agent; cognition enhancers; 2-{3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1-biphenyl-4-yl}cyclopropanecarboxylic acid |
| 03/16/2006 | US20060058310 Remedies for vertebral canal stenosis |
| 03/16/2006 | US20060058307 Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog |
| 03/16/2006 | US20060058304 Azaindole kinase inhibitors |
| 03/16/2006 | US20060058303 7-Phenylimidazo[1,2-b][1,2,4]triazine derivatives; treating anxiety; for example, 2-[4-(3-trifluoromethylimidazo[1,2-b][1,2,4]triazin-7-yl)pyridin-2-yl]-benzonitrile |
| 03/16/2006 | US20060058302 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases; example compound: 2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(2-ethyl-hexyl)-benzamide |
| 03/16/2006 | US20060058300 Intermediates of bupropion metabolites synthesis |
| 03/16/2006 | US20060058288 Severe sepsis preventive therapeutic agent |
| 03/16/2006 | US20060058278 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| 03/16/2006 | US20060058274 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/16/2006 | US20060058267 Pharmaceutical compositions comprising a NOS inhibitor |
| 03/16/2006 | US20060058253 Methods to reprogram splice site selection in pre-messenger rnas |
| 03/16/2006 | US20060058239 Use of the insulin-like-growth factor I isoform MGF for the treatment of neurological disorders |
| 03/16/2006 | US20060058225 Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease |
| 03/16/2006 | US20060057663 Novel g protein-coupled receptor protein and dna thereof |
| 03/16/2006 | US20060057648 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
| 03/16/2006 | US20060057218 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 03/16/2006 | US20060057210 for oral administration, reducing the range in daily dosages required to control pain in human patients; specified mean maximum plasma concentration |
| 03/16/2006 | US20060057203 Modified release formulations of oxcarbazepine and derivatives thereof |
| 03/16/2006 | US20060057185 Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person |
| 03/16/2006 | US20060057156 Materials and methods for inductions of immune tolerance |
| 03/16/2006 | DE102004038155A1 Physiologisch verträgliche Zusammensetzung enthaltend alpha-Liponsäure, Kreatin und ein Phospholipid Physiologically acceptable composition comprising alpha-lipoic acid, creatine and a phospholipid |
| 03/16/2006 | CA2580132A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 03/16/2006 | CA2580042A1 Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 03/16/2006 | CA2580034A1 Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| 03/16/2006 | CA2579768A1 Enzyme inhibitors and uses thereof |
| 03/16/2006 | CA2579720A1 A pharmaceutical composition for treating ataxia, multiple system atrophy or balance disorders |
| 03/16/2006 | CA2579540A1 The treatment of inflammatory disorders and pain |
| 03/16/2006 | CA2579353A1 Therapeutic strategy for treating autoimmune and degenerative diseases |
| 03/16/2006 | CA2579352A1 Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| 03/16/2006 | CA2579303A1 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| 03/16/2006 | CA2579204A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | CA2578996A1 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 03/16/2006 | CA2578990A1 Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine |
| 03/16/2006 | CA2578958A1 Acetylated starch or starch succinate for treatment of obesity or diabetes |
| 03/16/2006 | CA2578739A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | CA2578434A1 2-morpholino-4-pyrimidone compound |
| 03/16/2006 | CA2578395A1 Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| 03/16/2006 | CA2578290A1 Combination of organic compounds |
| 03/16/2006 | CA2577828A1 Methods of using death receptor ligands and cd20 antibodies |
| 03/16/2006 | CA2577610A1 Sigma receptor ligands |
| 03/16/2006 | CA2577408A1 Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators |
| 03/16/2006 | CA2576393A1 Novel derivatives of 3,5-seco-4-norcholestane and use thereof |
| 03/15/2006 | EP1634956A1 Recombinant adeno-associated virus vector for treatment of alzheimer disease |
| 03/15/2006 | EP1634873A1 Sigma receptor inhibitors |
| 03/15/2006 | EP1634872A1 Pyrazole derivatives as sigma receptor inhibitors |
| 03/15/2006 | EP1634865A1 Sertraline hydrochloride polymorphs |
| 03/15/2006 | EP1634602A2 Use of plants of the genus Sideritis for preventing and influencing disturbances correlated with a changed serotoninergic neurotransmission |
| 03/15/2006 | EP1634597A1 Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability |
| 03/15/2006 | EP1634594A1 Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators |